

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR

RESIGNATION OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The board of directors (the “**Board**”) of Shanghai Henlius Biotech, Inc. (the “**Company**”) announces that Ms. LIU Junhong (“**Ms. Liu**”) ceased to act as the employee representative supervisor of the third session of board of supervisors of the Company (“**the Board of Supervisors**”) due to adjustment to her work arrangement with effect from 31 December 2022.

Ms. Liu has confirmed that she has no disagreement with the Board or the Board of Supervisors and there are no other matters relating to her resignation that need to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited.

The Board and the Board of Supervisors expressed their gratitude to Ms. Liu for her contribution to the development of the Company during her tenure as the employee representative supervisor of the Company.

APPOINTMENT OF EMPLOYEE REPRESENTATIVE SUPERVISOR

The Board is also pleased to announce that the Company convened an employee representative meeting on 1 January 2023, during which Mr. YUAN Yexing (“**Mr. Yuan**”) is elected as the employee representative supervisor of the Board of Supervisors of the Company. Mr. Yuan’s term of office commences from 1 January 2023 until the expiry date of the third session of the Board of Supervisors.

The biographical details of Mr. Yuan are set out below:

Mr. Yuan, aged 38, has served as an auditing director of the Company since January 2023. He has also been a supervisor of the Company and a supervisor of Shanghai Henlius Biopharmaceuticals Co., Ltd., Shanghai Henlius Biologics Co., Ltd. and Shanghai Jollin Tech Co., Ltd., which are the subsidiaries of the Company, since January 2023. Before joining the Company, Mr. Yuan acted as an auditor in WelcoHuaGao Technology (Suzhou) Co., Ltd. (華高科技(蘇州)有限公司) from June 2005 to November 2012. From December 2012 to July 2015, he worked as an auditing manager in Minth Group Limited (stock code: 00425. HK). From July 2015 to September 2017, he also served as an auditing manager in Trina Solar Co., Ltd (stock code: 688599. SH). Mr. Yuan served as a senior auditing manager in Cobest Enterprise Development (Shanghai) Co., Ltd. from October 2017 to April 2018. He also served as a senior auditing manager in GCL System Integration Technology Co., Ltd. (stock code: 002506. SZ) from May 2018 to February 2021. From March

2021 to December 2022, he served as an auditing director in Shanghai Fosun Pharmaceutical (Group) Co., Ltd.. Mr. Yuan received his bachelor's degree in accounting in Nanjing University of Information Science & Technology in June 2005.

Mr. Yuan has entered into a service contract with the Company. Mr. Yuan will not receive additional remuneration from the Company to act as an employee representative supervisor of the Company.

Saved as disclosed above, as at the date of this announcement, Mr. Yuan has confirmed that he (i) does not hold any other positions in the Company or its subsidiaries; (ii) does not have any relationship with any directors, supervisors, senior management or substantial or controlling shareholders of the Company; and (iii) has not held any directorship or supervisor positions in any listed companies in the past three years. As at the date of this announcement, Mr. Yuan does not have any interest in any shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Saved as disclosed above, as at the date of this announcement, there is no other information in respect of Mr. Yuan that needs to be disclosed pursuant to Rule 13.51(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, and there is no other matter in respect of his appointment that needs to be brought to the attention of the shareholders of the Company.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Wenjie Zhang
Chairman

Hong Kong, 3 January 2023

As at the date of this announcement, the board of directors of the Company comprises Mr. Wenjie Zhang as chairman and the executive director, Mr. Qiyu Chen, Mr. Yifang Wu, Ms. Xiaohui Guan, Mr. Deyong Wen and Mr. Zihou Yan as the non-executive directors, and Mr. Tak Young So, Dr. Lik Yuen Chan, Dr. Guoping Zhao and Dr. Ruilin Song as the independent non-executive directors.